Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Haemonetics (HAE) has drawn fresh attention after reporting first quarter fiscal 2027 results, with sales of US$339.38 million and net income of US$33.01 million, alongside a US$391.25 million shelf registration tied to an ESOP related stock offering.
See our latest analysis for Haemonetics.
Haemonetics' recent earnings beat, higher revenue guidance and fresh clinical data around VASCADE MVP XL have coincided with a strong 90 day share price return of 61.31%. The 1 year total shareholder return of 68.96% signals building momentum rather than a short term spike.
If Haemonetics' recent move has you looking for other potential medical technology ideas, consider widening your search with the 44 healthcare AI stocks
Haemonetics' surge has come alongside higher guidance, fresh product data and an ESOP related shelf filing. That mix can reflect improving fundamentals or shifting enthusiasm. The next step is to see what the current valuation implies.
Most Popular Narrative: 6.3% Undervalued
Haemonetics closed at $90.80, while the most followed narrative places fair value at $96.90 using a discounted cash flow framework with an 8.0% range discount rate. That gap sits at the center of a broader story built around earnings power, margins and capital allocation over the next several years.
Enterprise-wide portfolio transformation, highlighted by the divestiture of low-margin businesses, disciplined capital deployment, and ongoing investment in automation and digital solutions, is driving substantial gross and operating margin expansion (guidance of 26–27% for FY26) and is likely to support further improvements in net margins and free cash flow conversion.
Read the complete narrative. Read the complete narrative.
Want to see what underpins that valuation gap for Haemonetics. The core of this narrative is a step change in profitability, a reset earnings base and a lower future earnings multiple than many peers. Curious which margin assumptions and growth profile support a fair value above the current price.
Result: Fair Value of $96.90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Haemonetics' story could change quickly if competition bites into NexSys, TEG or VASCADE, or if U.S.-focused demand slows and exposes that product concentration.
Next Steps
With mixed sentiment around Haemonetics, it helps to carefully consider both the potential upside and downside for yourself and to move quickly while the data is fresh by reviewing the 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Haemonetics?
If you are serious about sharpening your portfolio after looking at Haemonetics, use focused stock lists to quickly spot fresh ideas before the crowd catches on.
-
Target resilient returns by scanning 83 resilient stocks with low risk scores . This may help steady your portfolio when markets feel choppy.
-
Hunt for quality at a potential discount through the 50 high quality undervalued stocks . It filters for fundamentals many investors overlook.
-
Stack potential income streams by checking out the 10 dividend fortresses . It highlights companies with higher yielding payouts.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include HAE .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
